18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: Preliminary study

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 1, 2009, Pages 137-144

  Vercellino, Laetitia ^a   Bousquet, Guilhem ^a   Baillet, Georges ^a   Barré, Emmanuelle ^a   Mathieu, Olivier ^a   Just, Pierre Alexandre ^a   Desgrandchamps, François ^a   Misset, Jean Louis ^a   Hindié, Elif ^a   Moretti, Jean Luc ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

FDG; PET CT; Renal cell carcinoma; Sunitinib; Treatment monitoring

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; SUNITINIB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN HEMORRHAGE; CANCER PATIENT; CARCINOMATOSIS; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG TUMOR LEVEL; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOFT TISSUE METASTASIS; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KIDNEY TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; PROGNOSIS; SCINTISCANNING; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PYRROLES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 60849092923     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0527     Document Type: Article

References (30)

1. Remontet L, Buemi A, Velten M, et al. Cancer incidence and mortality in France during the period 1978 to 2000 [in French]. Invs 2003;217.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865.
3. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center Experience. Clin Cancer Res 2004;10:6302S.
4. Negrier S, Gomez F, Douillard JY, et al. Groupe Francais d'Immunotherapie. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie. World J Urol 2005;23:161.
5. Bay JO, Penault-Llorca F, Ravaud A, et al. New entities in pathological classification and new therapeutic options in renal cell carcinoma [in French]. Bull Cancer 2006;93:91.
6. Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290S.
7. Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007;13:680S.
8. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477. [Review; no abstract available]
9. Weiss RH, Lin PY. Kidney cancer: Identification of novel targets for therapy. Kidney Int 2006;69:224.
10. Morabito A, De Maio E, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. Oncologist 2006;11:753.
11. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:27.
12. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205.
14. 18F-FDG-PET in renal cell carcinoma. Rev Esp Med Nucl 2007;26:19.
15. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012.
16. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773.
17. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125.
18. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16.
19. Stierner U, Boijsen M, Suurküla M, et al. The value of PET-CT (positron emission tomography) in the treatment of metastatic renal cell carcinoma with sorafenib. J Clin Oncol 2007 ASCO Annual Meeting Proceedings, Part I, Vol. 25, No. 18S (June 20 Supplement), 2007:15621.
20. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059.
21. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571.
22. 18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24:5366.
23. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445.
24. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Mol Imaging 2006;33(Suppl 1):27.
25. Bhatt RS, Seth P, Sukhatme VP. Biomarkers for monitoring antiangiogenic therapy. Clin Cancer Res 2007;13:777s.
26. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR Am J Roentgenol 2007;189:360.
27. Holdsworth CH, Badawi RD, Manola JB, et al. CT and PET: Early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 2007;189:W324.
28. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind, phase III trial. Lancet 2007;370:2103.
29. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271.
30. Jac J, Amato RJ, Giessinger S, et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings, Vol. 26, No. 15S (May 20 Supplement), 2008:5113.